

# Next steps for NICE and key issues for the pharmaceutical industry 15<sup>th</sup> January 2015

# **CONDITIONS FOR USE OF TRANSCRIPTS:**

This document is intended to provide a timely reference for interested parties who are unable to attend the event to which it refers. Some portions are based on transcripts of proceedings and others consist of text submitted by speakers or authors, and are clearly marked as such. As such, apart from where it is indicated that the text was supplied by the speaker, it has not been possible for the transcript to be checked by speakers and so this portion of the document does not represent a formal record of proceedings. Despite best endeavours by Westminster Forum Projects and its suppliers to ensure accuracy, text based on transcription may contain errors which could alter the intended meaning of any portion of the reported content. Anyone who intends to publicly use or refer to any text based on the transcript should make clear that speakers have not had the opportunity for any corrections, or check first with the speaker in question. If in doubt please contact the forum first.

# **Contents**

About this Publication	3
<u>Agenda</u>	4
Session Chair's opening remarks Christian Dingwall, Partner, Hempsons (transcript)	6
Priorities for NICE in the health and social care system  Professor Gillian Leng, Deputy Chief Executive and Director of Health and Social Care, NICE (transcript)  Questions and comments from the floor (transcript)	7 10
The future for the Cancer Drugs Fund Professor Peter Clark, Chair, Cancer Drugs Fund (transcript) Questions and comments from the floor (transcript)	13 16
Implementing guidance in health and care - integration, commissioning and moving forward on safe staffing  Dr Joe McGilligan, Local Government Association Health and Wellbeing Champion and former Chair,  East Surrey Clinical Commissioning Group (transcript)  Dr Sunjai Gupta, Consultant and Senior Scientific Advisor, Health and Wellbeing Directorate,	19
Public Health England (transcript)  Professor David Croisdale-Appleby, Chair, Hft, Dementia UK and the Standing Commission on Carers (transcript)	21 23 25
Questions and comments from the floor with <b>Professor Gillian Leng</b> , Deputy Chief Executive and Director of Health and Social Care, NICE (transcript)	27
Session Chair's closing remarks Christian Dingwall, Partner, Hempsons (transcript)	35
Session Chair's opening remarks Christian Dingwall, Partner, Hempsons (transcript)	36
Accelerating innovation and developing new technologies  Dr Zahid Latif, Head of Healthcare, Innovate UK (transcript)	37
Next steps for medicines optimisation: safety, efficiency and improving outcomes  Professor Rob Darracott, Chief Executive, Pharmacy Voice (transcript)	41
Questions and comments from the floor (transcript)	44
The Pharmaceutical Price Regulation Scheme and the view from industry  Paul Catchpole, Director of Value and Access, ABPI (transcript)	47
<u>Developing partnerships, appraisals and value based assessments</u> Dr Julia Earnshaw, Vice President, Health Outcomes and Regulatory Affairs, GSK UK (transcript)  Nick Bason, Member, Executive Group, Patients Involved in NICE and Head of Policy and Communications,	52
Bowel Cancer UK (transcript)  Omar Ali, Formulary Development Pharmacist, Surrey and Sussex Healthcare NHS Trust (transcript)  Professor Gareth Evans, Clinical Lead, NICE Guidelines Development Group for Familial Breast Cancer,	54 56
Manchester Academic Health Science Centre (transcript)  Questions and comments from the floor with <b>Paul Catchpole</b> , Director of Value and Access, ABPI (transcript)	58 59
Session Chair's and Westminster Health Forum closing remarks Christian Dingwall, Partner, Hempsons (transcript) Steve Moat, Senior Producer, Westminster Health Forum (transcript)	67 68
<u>Press Links</u>	69
List of Delegates Registered for Seminar	70
Contributor Biographies	76
About the Core Sponsor of the Westminster Health Forum	79

Please be advised that speakers' PowerPoint presentations are included within the transcript itself, just beneath the relevant speaker's text. Please note that not all speakers are able to grant permission for us to include their slides.

# **About this Publication**

This publication reflects proceedings at the Westminster Health Forum Keynote Seminar: Next steps for NICE and key issues for the pharmaceutical industry held on 15<sup>th</sup> January 2015. The views expressed in the articles are those of the named authors, not those of the Forum or the sponsors, apart from their own articles.

Although Westminster Health Forum is grateful to all sponsors for the funding on which we depend, participation in events and publications is never conditional on being a sponsor. As well as funding ongoing operations, sponsorship enables the Forum to distribute complimentary copies of publications, and offer complimentary tickets for events, to Government ministers, parliamentarians and officials most involved in policy.

This publication is copyright. Its copying, in whole or in part, is not permitted without the prior written consent of the publishers. However, extracts of the text may be reproduced for academic or review purposes, subject to the conditions of use outlined in the previous page, providing they are accurate, are not used in a misleading context and the author, their organisation and the Westminster Health Forum are acknowledged. We would also appreciate being informed.

## **Westminster Health Forum**

UK Headquarters 4 Bracknell Beeches Old Bracknell Lane West Bracknell Berkshire RG12 7BW

T: 01344 864796 F: 01344 420121 publications@westminsterforumprojects.co.uk

### **Directors**

Peter van Gelder Chris Whitehouse